Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-09-2008 | Retinal Disorders

A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (Case reports)

Authors: Mitzy E. Torres-Soriano, Gerardo García-Aguirre, Verónica Kon-Jara, Orlando Ustariz-Gonzáles, Maura Abraham-Marín, Michael D. Ober, Hugo Quiroz-Mercado

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 9/2008

Abstract

Background

We report the use of intravitreal bevacizumab as a new option in the treatment of central serous chorioretinopathy (CSC).

Methods

Five eyes with retinal pigment epithelium (RPE) leaks secondary to CSC received intravitreal bevacizumab (2.5 mg/0.1 cc), and underwent best corrected visual acuity, fluorescein angiography and optical coherent tomography before, 1, 3 and 6 months after treatment.

Results

All patients showed improvement in visual acuity, fluorescein angiographic leakage, and reduced or resolved neurosensory detachment following treatment.

Conclusions

Intravitreal injection of bevacizumab was associated with visual improvement and reduced neurosensory detachment without adverse events in patients with CSC. Although these results are promising, further investigations would be helpful to understand this therapy for patients with CSC.

Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372PubMedCrossRef

Battaglia Parodi M, Da Pozzo S, Ravalico G (2003) Photodynamic therapy in chronic central serous chorioretinopathy. Retina 23:235–237PubMedCrossRef

Bujarborua D (2005) CSR: Idiopathic central serous chorioretinopathy. Jaypee Brothers, New Delhi

Burumcek E, Mudun A, Karacorlu S, Arslan MO (1997) Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology 104:616–622PubMed

Cardillo Piccolino F, Eandi CM, Ventre L et al (2003) Photodynamic therapy for chronic central serous chorioretinopathy. Retina 23:752–763PubMedCrossRef

Chan WM, Lam DS, Lai TY et al (2003) Choroidal vascular remodeling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 87:1453–1458PubMedCrossRef

Colucciello M (2006) Choroidal neovascularization complication photodynamic therapy for central serous retinopathy. Retina 26:239–242PubMedCrossRef

Gass JD (1967) Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 63(Suppl):1–139PubMed

Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U (2007) Tübingen bevacizumab study group. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48:2814–2823PubMedCrossRef

10.

Ober MD, Eandi CM, Jampol LM, Fine HF, Yannuzzi LA (2007) Focal retinal pigment epithelium breaks in central serous chorioretinopathy. Retinal Cases and Brief Reports 1(4):271–274CrossRef

11.

Ober MD, Yannuzzi LA, Do DV et al (2005) Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology 112:2088–2094PubMedCrossRef

12.

Pikkel J, Beiran I, Ophir A, Miller B (2002) Acetazolamide for central serous retinopathy. Ophthalmology 109:1723–1725PubMedCrossRef

13.

Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, Johnson PT, Fisher SK, Perlman I, Loewenstein A (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26:262–269PubMedCrossRef

14.

Spaide RF, Laud K, Fine HF et al (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383–390PubMedCrossRef

15.

Von Graefe A (1866) Ueber centrale recidivierende Retinitis. Graefes Arch Clin Exp Ophthalmol 12:211–215

Title: A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (Case reports)
Authors: Mitzy E. Torres-Soriano
Gerardo García-Aguirre
Verónica Kon-Jara
Orlando Ustariz-Gonzáles
Maura Abraham-Marín
Michael D. Ober
Hugo Quiroz-Mercado
Publication date: 01-09-2008
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 9/2008
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-008-0856-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (Case reports)

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2008

Retrobulbar hemodynamic parameters in pseudoexfoliation syndrome and pseudoexfoliative glaucoma

Surgical treatment of myopic strabismus fixus: a graded approach

Videonystagmography as a tool to assess blepharospasm before and after botulinum toxin injection

Subconjunctival antisense oligonucleotides targeting TNF-α influence immunopathology and viral replication in murine HSV-1 retinitis

Experimental study on antiviral activity of silicone oil in vitro

The neuropeptide NAP provides neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush